Radium-223 in metastatic castration resistant prostate cancer

Asian Journal of Andrology

Volumn 16, Issue 3, 2014, Pages 348-353

  Vuong, Winston ^a   Sartor, Oliver ^b   Pal, Sumanta K ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alpharadin; Bone metastases; Metastatic castration resistant prostate cancer; Radiopharmaceuticals; Radium 223; Xofigo

Indexed keywords

ABIRATERONE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; PLACEBO; RADIUM CHLORIDE RA 223; SAMARIUM 153; SIPULEUCEL T; STRONTIUM 89; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM;

ANEMIA; BLOOD TOXICITY; BONE PAIN; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL DEVELOPMENT PLAN; DIARRHEA; DRUG APPROVAL; DRUG EXCRETION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LEUKOPENIA; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MOLECULAR BIOLOGY; NAUSEA AND VOMITING; NEUTROPENIA; REVIEW; THROMBOCYTOPENIA; ANIMAL; BONE NEOPLASMS; CLINICAL TRIAL (TOPIC); DRUG SCREENING; MALE; MOUSE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY;

ANIMALS; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900502158     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.127812     Document Type: Review

References (43)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30
2. Pal SK, Sartor O. Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl 2011; 13: 683-9
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20
5. FDA approval for docetaxel. Available from: Http://www.cancer.gov/ cancertopics/ druginfo/fda-docetaxel. [Last accessed on 2011 Jul 03
6. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: Randomised open-label trial. Lancet 2010; 376: 1147-54
7. FDA approval letter: Cabazitaxel. Available from: Http://www.accessdata. fda. gov/drugsatfda-docs/nda/2010/201023s000Approv.pdf. [Last accessed on 2013 Jan 06
8. FDA approval letter: Provenge. Available from: Http://www.cancer.gov/ cancertopics/ druginfo/fda-sipuleucel-T. [Last accessed on 2013 Nov 23
9. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22
10. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
11. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-48
12. FDA approval for abiraterone acetate. Available from: Http://www.cancer.gov/ cancertopics/druginfo/fda-Abirateroneacetate. [Last accessed on 2012 Jan 06
13. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-97
14. Medivation and astellas announce the phase 3 PREVAIL trial of enzalutamide meets both co-primary endpoints of overall survival and radiographic progression-free survival in chemotherapy-naive patients with advanced prostate cancer. Available from: Http://www.investors.medivation.com/ releasedetail.cfm?.ReleaseID=798880. [Last accessed on 2013 Nov 23
15. FDA approval for enzalutamide. Available from: Http://www.cancer.gov/ cancertopics/ druginfo/fda-enzalutamide. [Last accessed on 2013 Jan 06
16. Sartor O. Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol 2004; 6 Suppl 10: S3-12
17. Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27: 954-8
18. Porter AT. Strontium-89 (Metastron) in the treatment of prostate cancer metastatic to bone. Eur Urol 1994; 26 Suppl 1: 20-5
19. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-23
20. FDA approval leeter for xofigo. Available from: Http://www.accessdata. fda.gov/ drugsatfda-docs/appletter/2013/203971Orig1s000ltr.pdf. [Last accessed on 2013 Nov 22
21. Brady D, Parker CC, O'Sullivan JM. Bone-Targeting radiopharmaceuticals including radium-223. Cancer J 2013; 19: 71-8
22. Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: Potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res 2013; 5: 1-14
23. Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001; 28: 788-98
24. Henriksen G, Breistø. K, Bruland Ø.S, Fodstad Ø., Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle- emitting (223) Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002; 62: 3120-5
25. Henriksen G, Fisher DR, Roeske JC, Bruland ø.S, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: Comparison with the beta-emitter 89Sr in mice. J Nucl Med 2003; 44: 252-9
26. Nilsson S, Larsen RH, Foss SD, Balteskard L, Borch KW, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005; 11: 4451-9
27. Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2013; 40: 1384-93
28. Nilsson S, Franzé. L, Parker C, Tyrrell C, Blom R, et al. Bone-Targeted radium-223 in symptomatic, hormone-refractory prostate cancer: Randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8: 587-94
29. Nilsson S, Franzé. L, Parker C, Tyrrell C, Blom R, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer 2013; 11: 20-6
30. Nilsson S, Strang P, Aksnes AK, Franzé. L, Olivier P, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012; 48: 678-86
31. Parker CC, Pascoe S, Chodacki A, O'Sullivan JM, Germ JR, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 2013; 63: 189-97
32. Vogelzang NJ, Parker C, Nilsson S, Coleman RE, O'Bryan-Tear CG, et al. Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA). ASCO Meeting Abstracts 2013; 31: 11
33. Sartor AO, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, et al. Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA). ASCO Meeting Abstracts 2012; 30: 4551
34. Sartor AO, Amariglio R, Wilhelm S, Garcia-Vargas JE, O'Bryan-Tear CG, et al. Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes ASCO Meeting Abstracts 2013; 31: 5080
35. Nilsson S, Vogelzang NJ, Sartor AO, Bottomley D, Coleman RE, et al. 1.5-year post-Treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study. ASCO Meeting Abstracts 2014; 32: 9
36. Vogelzang NJ, Helle SI, Johannessen DC, O'Sullivan JM, Garcia-Vargas JE, et al. Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial. ASCO Meeting Abstracts 2013; 31: 5068
37. O'Sullivan J, Widmark DCJ, Syndikus I, James N, Dall'Oglio M, et al. Hematologic safety of radium-223 dichloride (Ra-223) in the phase 3 ALSYMPCA trial in castration-resistant prostate cancer (CRPC) patients with bone metastases:Baseline prognostic factor subgroup analysis. ESMO/ECCO Proc 2013; 49: S688
38. Nilsson S, Sartor AO, Bruland OS, Fang F, Aksnes AK, et al. Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases ASCO Meeting Abstracts 2013; 31: 5038
39. Medivation press release: PREVAIL enrollment. Available from: Http://www. investors.medivation.com/releasedetail.cfm?.ReleaseID=680579. [Last accessed on 2013 Jan 04
40. Culine S, El Demery M, Lamy PJ, Iborra F, Avanc̈. C, et al. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007; 178: 844-8
41. Research to practice: Clinical use of radium-223 Available from: Http://www. researchtopractice.com/PCUTT112/Video/14. [Last accessed on 2013 Nov 24
42. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, et al. Intermittent versus continuous androgen Deprivation in prostate cancer. N Engl J Med 2013; 368: 1314-25
43. Morris MJ, Hammers HJ, Sweeney C, Antonarakis ES, Cho SY, et al. Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): Phase I Prostate Cancer Clinical Trials Consortium Study. ASCO Meeting Abstracts 2013; 31: 5021.